Drug-resistant infections are winning.
people worldwide have died of a drug-resistant infection. That is about one every 25 seconds.
The two tools we have run into the same wall.
A fixed drug can’t keep up with an infection that keeps changing.
The drug works until the bacteria change.
An antibiotic knocks the infection back. Resistant survivors regrow, and the same drug no longer works. Bacteria evolve resistance faster than new drugs arrive, and few are coming.
That is the problem Myx was built to solve.
A patient-matched phage, evolved and produced on site.
Three steps run inside one instrument, from the patient’s isolate to the matched dose.
Every run, measured on screen.
Each run is one patient and one infection, tracked from the first round of selection to a sequenced, release-tested dose.
Better medicine, and a business built to reach patients.
We start where the bar is lower.
We begin with topical rare-disease indications, where the regulatory bar is lower and there is more than one route to the FDA.
We own clean freedom to operate.
We evolve the phage rather than engineer it, so the work stays clear of the engineered-phage patents and the path to the clinic stays ours.
Made where the patient is.
One instrument runs evolve, match and produce on site, turning a manual craft practiced at a few specialist centers into something a hospital can run.
A need the pipeline can’t meet.
Resistance keeps rising while few new antibiotics are coming. A therapy that adapts to each infection does not run out the way a fixed drug does.
Bring us the infection nothing else can treat.
Clinicians, hospitals, investors, and advisors each have a path. Tell us where you fit and we will take it from there.